It is important to understand how clinical trials work before considering whether to participate in one. Clinical trials raise important questions about understanding and consent. There is always a risk that treatment will be less effective, or even ineffective. You should always discuss these issues with your doctor, and make sure you fully understand the options and risks available before consenting to participating in a trial.
Phase III Trials
- Bendamustine and Rituximab versus R-CHOP/R-CVP
- GA101 (aka RO5072759) and Bendamustine versus Bendamustine
- Ofatumumab anti-CD20 monoclonal antibody versus Rituximab
- Ofatumumab and Bendamustine versus Bendamustine
Phase II Trials
- GA101 (aka RO5072759) anti-CD20 monoclonal antibody versus Rituximab
- Navitoclax (aka ABT-263) Bcl-2 inhibitor
- Ofatumumab anti-CD20 monoclonal antibody in older patients
- SB1518 kinase inhibitor
Phase I Trials
- AEG35156 XIAP antisense
- AT7519M kinase inhibitor
- Imetelstat telomerase inhibitor in young patients
- Inotuzumab Ozogamicin anti-CD22 monoclonal antibody
- Lucatumumab anti-CD40 monoclonal antibody + Bendamustine
- RO4929097 gamma-secretase inhibitor
Resources on Clinical Trials
